ClinicalTrials.gg
CompletedNCT05046184UNIKETUpdated Oct 8, 2026Results posted

Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

A Phase 2 interventional study of Ketamine Hydrochloride and Midazolam injection in Major Depressive Disorder and Healthy Controls, sponsored by University of Texas Southwestern Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by University of Texas Southwestern Medical Center · Phase 2, Interventional, and Other

How we know

Updated Oct 8, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies testing ketamine in Depressive Disorder, Major — 21 open to participants now, 26 under way, 5 of them phase 3. Ketamine · Depressive Disorder, Major.

Enrollment
15th of 89
104 · median 38
Started
2022
with 5 others
Phase 2
22 of 89
7 open now
Registered
64th of 89
by date

Among the 89 studies testing ketamine in Depressive Disorder, Major, this one is the 15th largest by enrollment, is one of 6 that started in 2022, is one of 22 in phase 2, and was the 64th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

21 of the 89 studies testing ketamine in Depressive Disorder, Major are open now, in 9 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing ketamine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The study is investigating dysfunctions in neurocircuitry in regards to irritability with healthy controls (HC) and individuals with Major Depressive Disorder (MDD) by performing MRIs. The MDD group will also be randomized to receive ketamine or midazolam to investigate changes post-treatment in neurocircuitry with regards to irritability.

Read the detailed description

The proposed study aims to 1 (Aim 1) identify dysfunctions in neurocircuitry that engender irritability, and (Aim 2) determine how changes in neurocircuit function related to change in irritability. We will accomplish Aim 1 with resting-state and frustrative nonreward (FNR) task-based fMRI data from n=30 HCs and n=60 subjects with MDD ((Fig 3). For Aim 2, we will randomize the MDD cohort (n=60; same as Aim 1) to 2 weeks of twice-weekly 40-minutes long intravenous infusion of either ketamine (0.5 mg/kg) or midazolam (0.02 mg/kg) in a double-blind parallel-arm fashion, and by repeating clinical assessments and fMRI scans after the last infusion. The central hypothesis of the proposed study is that striatum is a key hub in the neurocircuitry of irritability, and that treatment-related improvement in irritability is associated with normalization of these neurocircuit functioning.

03

Conditions studied

  • Major Depressive Disorder
  • Healthy Controls

Keywords

  • major depressive disorder
  • MDD
  • depression
  • depressive disorder
  • depression symptoms
  • healthy controls
  • irritability
  • ketamine
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, 18-65 years of age and body weight less than or equal to 120 kg on baseline visit.
  2. Participants must have a level of understanding of the English language sufficient to agree to all tests and examinations required by the study and must be able to participate fully in the process.
  3. For Healthy Controls: Subjects must be free of any lifetime psychiatric condition based on the Mini-International Neuropsychiatric Interview (MINI). For MDD: Subjects must meet (DSM-5) criteria for current unipolar depression [major depressive disorder (MDD) or persistent depressive disorder (PDD) in a current major depressive episode (MDE)] based on MINI.
  4. A woman of who is sexually active with a male must agree to use an acceptable method of [defined as either one highly effective (permanent sterilization, intrauterine device or hormonal implant) or two other forms of contraception (such as oral contraceptive pill and condom)] to avoid pregnancy throughout the study. Throughout the study and for 90 days (one spermatogenesis cycle) after receiving the last dose of study drug (ketamine/midazolam) man who is sexually active with a woman of childbearing potential must use an acceptable method of contraception (described above) with his female partner and must agree not to donate sperm.
  5. Subjects must either be free of psychotropic medications (including antidepressants, antipsychotics, benzodiazepines, mood stabilizers, sedative/hypnotics, dopamine agonists, stimulants, buspirone, and triptans) and certain anticonvulsants (topiramate and levetiracetam) or be stable on these medications for four weeks prior to the baseline visit [first magnetic resonance imaging (MRI) scan].
  6. Subjects with MDD should be willing to participate in neuroimaging scans before and after infusions, and be willing to undergo infusions with study drug.

Exclusion criteria

Exclusion Criteria:

  1. Lifetime diagnosis of schizophrenia or any psychotic disorder, bipolar disorder, pervasive developmental disorder or intellectual development disorder.
  2. Current diagnosis of obsessive-compulsive disorder, anorexia nervosa or bulimia. Comorbid anxiety, stress and trauma-related disorders are permitted as long as unipolar depression is the primary diagnosis.
  3. Diagnosis of a moderate or severe substance use disorder within the past 6 months per MINI; all subjects must have a negative urine toxicology test on the day of the MRI, prior to the scan.
  4. Female subjects who are pregnant, nursing, for may become pregnant. Women of must have a negative urine pregnancy test on the day of the fMRI, prior to scan, and on days of study drug infusion, prior to infusion.
  5. Any unstable medical illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, immunologic, or hematologic disease.
  6. Inadequately treated obstructive sleep apnea (STOP-Bang score of 5-8 if untreated, if using positive airway pressure device then past-month apnea hypopnea index ≥ 15 per hour representing moderate or higher severity).
  7. Presence of a significant neurological disease such as Parkinson's disease, primary or secondary seizure disorders, intracranial tumors, or severe head trauma.
  8. Presence of neurocognitive or dementing disorders.
  9. abnormalities of laboratories, physical examination (including unstable hypertension - systolic blood pressure >170, diastolic blood pressure >100), or at screening visit.
  10. Subjects judged to be at serious and imminent suicidal or homicidal risk by the PI or another study-affiliated psychiatrist.
  11. Any to MRI, including pacemakers or metallic objects in the body.
  12. Any claustrophobia or other conditions which may result in inability to lie still in the MRI scanner for 1 hour or more.
  13. Allergy to ketamine or midazolam in subjects with MDD.
  14. Must not be on any prohibited concomitant medication.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (actual)

Study arms

  • No intervention
    Healthy Controls

    Healthy controls will undergo clinician assessments and fMRI to compare to MDD group.

  • Active comparator
    MDD - Ketamine

    Participants with MDD who have completed all baseline assessments including pre-treatment fMRI scan randomly allocated to receive four ketamine infusions.

    Drug: Ketamine Hydrochloride

  • Placebo comparator
    MDD - Midazolam

    Participants with MDD who have completed all baseline assessments including pre-treatment fMRI scan randomly allocated to receive four midazolam infusions.

    Drug: Midazolam injection

Interventions

  • DrugKetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of ketamine (0.5 mg/kg). Ketamine will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.

  • DrugMidazolam injection

    Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of midazolam (0.02 mg/kg). Midazolam will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.

06

What researchers measure

Primary outcomes

  1. Resting State Functional Connectivity.

    Functional connectivity refers to the standardized correlation between resting state BOLD signal measured by fMRI of 7 striatal regions and habenula region of the brain (higher correlation means higher connectivity). Parcels from the striatal regions of the Schaefer atlas (2018) were assigned to the 7 resting state networks outlined by Yeo (2011) (i.e. Schaefer-Yeo atlas was used). Correlation coefficient represents a Fisher Z-transformed coefficient.

    Time frame: Baseline

  2. Striatal Response to Frustrative Nonreward (FNR).

    Difference between striatal response to frustrative nonreward (FNR) vs striatal response to positive feedback on the Affective Posner 3 task, as measured by the estimated difference in BOLD (Blood Oxygen Level Dependent) signal within the striatum regions of the brain (beta estimate from general linear test; from gltsym in AFNI's afniproc command). 7 regions correspond to those outlined by Schaefer-Yeo atlas 7-network version.

    Time frame: Baseline

  3. Treatment-related Change in Striatum-habenula Functional Connectivity.

    Functional connectivity refers to the standardized correlation between resting state BOLD signal measured by fMRI of 7 striatal regions and habenula region of the brain (higher correlation means higher connectivity). Parcels from the striatal regions of the Schaefer atlas (2018) were assigned to the 7 resting state networks outlined by Yeo (2011) (i.e. Schaefer-Yeo atlas was used). MDD participants only. Correlation coefficient represents a Fisher Z-transformed coefficient.

    Time frame: Assessed at baseline and end of treatment. See outcome measure 1 for baseline visit reporting

  4. Treatment-related Change in Striatal Response to FNR.

    Difference between striatal response to frustrative nonreward (FNR) vs striatal response to positive feedback on the Affective Posner 3 task, as measured by the estimated difference in BOLD (Blood Oxygen Level Dependent) signal within the striatum regions of the brain (beta estimate from general linear test; from gltsym in AFNI's afniproc command). 7 regions correspond to those outlined by Schaefer-Yeo atlas 7-network version.

    Time frame: Baseline, at 14 days. See outcome measure 2 for baseline timepoint data

Secondary outcomes

  1. Change in Symptoms of Irritability After Two Weeks of Twice-weekly Infusions of Ketamine Versus Midazolam.

    Symptoms of irritability will be measured Concise Associated Symptom Tracking scale (CAST-IRR) where possible scores range from 5-25 and higher scores indicate greater severity of irritability. Reported scores represent change in scale units from baseline.

    Time frame: 14 days (end of treatment)

  2. Change in Symptoms of Depression (Including Suicidal Ideation) Measured by MADR Scale

    Possible scores range from 0 to 60 where higher scores indicate worse outcome. Reported scores represent change in scale units from baseline

    Time frame: 14 days (end of treatment)

  3. Change in Symptoms of Depression Measured by QIDS Report

    Possible scores range from 0 to 27 where higher scores indicate worse outcome. Reported scores represent change in scale units from baseline

    Time frame: 14 days (end of treatment)

  4. Change in Symptoms of Anxious Arousal Measured by MAS Questionnaire

    Possible scores range from 10-50 where higher scores indicate worse outcome. Reported scores represent change in scale units from baseline

    Time frame: 14 days (end of treatment)

  5. Number of Participants That Met Criteria for Experiencing an Anger Attack on Massachusetts General Hospital Anger Attack Questionnaire (AAQ)

    Anger attacks were assessed for using the Massachusetts General Hospital Anger Attack Questionnaire (AAQ), which asks about symptoms of anger attacks. If certain criteria on the AAQ are met, the individual is counted as having experienced an anger attack.

    Time frame: Baseline, at 14 days

  6. Change in Brief Psychiatric Rating Scale Positive Domain

    The Brief Psychiatric Rating Scale (BPRS) is a clinician-administered assessment used to capture acute behavioral changes throughout treatment. We used only the 4 items assessing positive symptoms of psychosis such as conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content for this study. Each item is rated on a 7-point scale, ranging from 1 (not observed) to 7 (very severe), with a total score range from 4-28, where higher scores indicate psychiatric symptoms. MDD participants only.

    Time frame: Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)

  7. Change in Clinician-Administered Dissociative Symptom Scale

    The Clinician-Administered Dissociative States Scale (CADSS) was used before and after each infusion to assess the severity of dissociative symptoms associated with study drug administration. Possible scores range from 0-5 where higher scores indicate worse outcome/more severe symptoms. MDD participants only

    Time frame: Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)

  8. Number of Participants Reporting Symptoms From the Patient Rated Inventory of Side Effects (PRISE)

    The Patient Rated Inventory of Side Effects (PRISE) is a clinician administered questionnaire used to qualify side effects by identifying and evaluating the tolerability of each symptom. Symptoms are grouped into domains by organ class. Numbers reported here reflect number of participants who reported at least one symptom in a given class over the total study duration, from baseline to study exit. Please note that many "other" side effects are symptoms of depression, and many were present at baseline since this was an MDD population. Here, we report the number of participants who endorsed symptoms from each organ class of symptoms.

    Time frame: Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)

07

Results

Posted Oct 8, 2026

Participant flow

Participant flow — Overall Study
MilestoneHealthy ControlMDD - MidazolamMDD - Ketamine
Started423131
Completed423029
Not completed012

Outcome measures

PrimaryResting State Functional Connectivity.

Functional connectivity refers to the standardized correlation between resting state BOLD signal measured by fMRI of 7 striatal regions and habenula region of the brain (higher correlation means higher connectivity). Parcels from the striatal regions of the Schaefer atlas (2018) were assigned to the 7 resting state networks outlined by Yeo (2011) (i.e. Schaefer-Yeo atlas was used). Correlation coefficient represents a Fisher Z-transformed coefficient.

Time frame:
Baseline
Reported as:
Mean · Fisher z correlation coefficient
Resting State Functional Connectivity.
Fisher z correlation coefficientHealthy ControlMDD - KetamineMDD - Midazolam
Striatal network 1 - Habenula functional connectivity-0.002355 ± 0.092290.02525 ± 0.076180.04504 ± 0.09565
Striatal network 2 - Habenula functional connectivity-0.005570 ± 0.01205-0.0006422 ± 0.009798-0.003755 ± 0.008074
Striatal network 3 - Habenula functional connectivity-0.003135 ± 0.042400.007026 ± 0.045910.005655 ± 0.042714
Striatal network 4 - Habenula functional connectivity-0.002556 ± 0.0084710.0003311 ± 0.008567-0.001633 ± 0.007936
Striatal network 5 - Habenula functional connectivity-0.0006443 ± 0.017340.002509 ± 0.012500.0008957 ± 0.01424
Striatal network 6 - Habenula functional connectivity0.0002023 ± 0.0074280.001734 ± 0.0084580.0018644074 ± 0.007666
Striatal network 7 - Habenula functional connectivity0.0005949 ± 0.0085840.001678 ± 0.0092900.0007463 ± 0.008234
PrimaryStriatal Response to Frustrative Nonreward (FNR).

Difference between striatal response to frustrative nonreward (FNR) vs striatal response to positive feedback on the Affective Posner 3 task, as measured by the estimated difference in BOLD (Blood Oxygen Level Dependent) signal within the striatum regions of the brain (beta estimate from general linear test; from gltsym in AFNI's afniproc command). 7 regions correspond to those outlined by Schaefer-Yeo atlas 7-network version.

Time frame:
Baseline
Reported as:
Mean · Estimated BOLD signal (beta estimate)
Striatal Response to Frustrative Nonreward (FNR).
Estimated BOLD signal (beta estimate)Healthy ControlMDD - KetamineMDD - Midazolam
Contrast of striatal network 1 activation following frustrating vs positive feedback0.008095 ± 0.18800.0299566552 ± 0.23753275990.0575584643 ± 0.2340562227
Contrast of striatal network 2 activation following frustrating vs positive feedback0.02017 ± 0.1006-0.002985828 ± 0.10592108650.0429733571 ± 0.0997051875
Contrast of striatal network 3 activation following frustrating vs positive feedback-0.015433282 ± 0.1624008534-0.012460897 ± 0.14470453310.027166 ± 0.1874875272
Contrast of striatal network 4 activation following frustrating vs positive feedback0.009815 ± 0.10410.0065397241 ± 0.10685668890.0501653214 ± 0.1030575279
Contrast of striatal network 5 activation following frustrating vs positive feedback0.01036 ± 0.13460.0424085517 ± 0.10158051360.0648926429 ± 0.1293505982
Contrast of striatal network 6 activation following frustrating vs positive feedback0.006723 ± 0.14020.0016498966 ± 0.12871437060.0320963929 ± 0.1118624523
Contrast of striatal network 7 activation following frustrating vs positive feedback0.02340 ± 0.12370.03740475 ± 0.11287585720.03740475 ± 0.1110403024
PrimaryTreatment-related Change in Striatum-habenula Functional Connectivity.

Functional connectivity refers to the standardized correlation between resting state BOLD signal measured by fMRI of 7 striatal regions and habenula region of the brain (higher correlation means higher connectivity). Parcels from the striatal regions of the Schaefer atlas (2018) were assigned to the 7 resting state networks outlined by Yeo (2011) (i.e. Schaefer-Yeo atlas was used). MDD participants only. Correlation coefficient represents a Fisher Z-transformed coefficient.

Time frame:
Assessed at baseline and end of treatment. See outcome measure 1 for baseline visit reporting
Reported as:
Mean · Fisher z correlation coefficient
Treatment-related Change in Striatum-habenula Functional Connectivity.
Fisher z correlation coefficientMDD - KetamineMDD - Midazolam
Striatal network 1 - Habenula functional connectivity-0.0009734 ± 0.05776-0.01185 ± 0.07534
Striatal network 2 - Habenula functional connectivity-0.002656739 ± 0.0160103506-0.000169 ± 0.0100583457
Striatal network 3 - Habenula functional connectivity-0.012500043 ± 0.037625987-0.000802696 ± 0.037625987
Striatal network 4 - Habenula functional connectivity-0.004466304 ± 0.01229433080.0017146522 ± 0.0091285944
Striatal network 5 - Habenula functional connectivity0.003012087 ± 0.0155766520.0029876957 ± 0.0126743798
Striatal network 6 - Habenula functional connectivity-0.001122 ± 0.00927337790.0013288696 ± 0.0109347196
Striatal network 7 - Habenula functional connectivity-0.001283609 ± 0.01218994560.0000793913 ± 0.0108864131
PrimaryTreatment-related Change in Striatal Response to FNR.

Difference between striatal response to frustrative nonreward (FNR) vs striatal response to positive feedback on the Affective Posner 3 task, as measured by the estimated difference in BOLD (Blood Oxygen Level Dependent) signal within the striatum regions of the brain (beta estimate from general linear test; from gltsym in AFNI's afniproc command). 7 regions correspond to those outlined by Schaefer-Yeo atlas 7-network version.

Time frame:
Baseline, at 14 days. See outcome measure 2 for baseline timepoint data
Reported as:
Mean · Estimated BOLD signal (beta estimate)
Treatment-related Change in Striatal Response to FNR.
Estimated BOLD signal (beta estimate)MDD - KetamineMDD - Midazolam
Contrast of striatal network 1 activation following frustrating vs positive feedback-0.043221536 ± 0.2355486241-0.049248448 ± 0.2134111013
Contrast of striatal network 2 activation following frustrating vs positive feedback0.0277769643 ± 0.07855267450.0244194138 ± 0.093963263
Contrast of striatal network 3 activation following frustrating vs positive feedback0.02633 ± 0.09821220410.0057957931 ± 0.1500521724
Contrast of striatal network 4 activation following frustrating vs positive feedback0.034981931 ± 0.09167525340.03323825 ± 0.0902350144
Contrast of striatal network 5 activation following frustrating vs positive feedback0.0333037857 ± 0.10052256030.0322243103 ± 0.1231102155
Contrast of striatal network 6 activation following frustrating vs positive feedback0.0173799286 ± 0.09736189070.0228358276 ± 0.0953103359
Contrast of striatal network 7 activation following frustrating vs positive feedback0.0299317857 ± 0.06856363150.0282071034 ± 0.0950889413
SecondaryChange in Symptoms of Irritability After Two Weeks of Twice-weekly Infusions of Ketamine Versus Midazolam.

Symptoms of irritability will be measured Concise Associated Symptom Tracking scale (CAST-IRR) where possible scores range from 5-25 and higher scores indicate greater severity of irritability. Reported scores represent change in scale units from baseline.

Time frame:
14 days (end of treatment)
Reported as:
Mean · Score on a scale
Change in Symptoms of Irritability After Two Weeks of Twice-weekly Infusions of Ketamine Versus Midazolam.
Score on a scaleMDD: KetamineMDD: Midazolam
Change in Symptoms of Irritability After Two Weeks of Twice-weekly Infusions of Ketamine Versus Midazolam.-4.87 ± 4.66-2.87 ± 3.91
SecondaryChange in Symptoms of Depression (Including Suicidal Ideation) Measured by MADR Scale

Possible scores range from 0 to 60 where higher scores indicate worse outcome. Reported scores represent change in scale units from baseline

Time frame:
14 days (end of treatment)
Reported as:
Mean · Score on a scale
Change in Symptoms of Depression (Including Suicidal Ideation) Measured by MADR Scale
Score on a scaleMDD: KetamineMDD: Midazolam
Change in Symptoms of Depression (Including Suicidal Ideation) Measured by MADR Scale-13.84 ± 9.93-8.95 ± 9.94
SecondaryChange in Symptoms of Depression Measured by QIDS Report

Possible scores range from 0 to 27 where higher scores indicate worse outcome. Reported scores represent change in scale units from baseline

Time frame:
14 days (end of treatment)
Reported as:
Mean · Score on a scale
Change in Symptoms of Depression Measured by QIDS Report
Score on a scaleMDD: KetamineMDD: Midazolam
Change in Symptoms of Depression Measured by QIDS Report-5.90 ± 4.28-3.39 ± 3.90
SecondaryChange in Symptoms of Anxious Arousal Measured by MAS Questionnaire

Possible scores range from 10-50 where higher scores indicate worse outcome. Reported scores represent change in scale units from baseline

Time frame:
14 days (end of treatment)
Reported as:
Mean · Score on a scale
Change in Symptoms of Anxious Arousal Measured by MAS Questionnaire
Score on a scaleMDD: KetamineMDD: Midazolam
Change in Symptoms of Anxious Arousal Measured by MAS Questionnaire-4.94 ± 5.56-3.10 ± 5.01
SecondaryNumber of Participants That Met Criteria for Experiencing an Anger Attack on Massachusetts General Hospital Anger Attack Questionnaire (AAQ)

Anger attacks were assessed for using the Massachusetts General Hospital Anger Attack Questionnaire (AAQ), which asks about symptoms of anger attacks. If certain criteria on the AAQ are met, the individual is counted as having experienced an anger attack.

Time frame:
Baseline, at 14 days
Reported as:
Count of participants · Participants
Number of Participants That Met Criteria for Experiencing an Anger Attack on Massachusetts General Hospital Anger Attack Questionnaire (AAQ)
ParticipantsMDD: KetamineMDD: Midazolam
Baseline105
Study exit (14 days)34
SecondaryChange in Brief Psychiatric Rating Scale Positive Domain

The Brief Psychiatric Rating Scale (BPRS) is a clinician-administered assessment used to capture acute behavioral changes throughout treatment. We used only the 4 items assessing positive symptoms of psychosis such as conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content for this study. Each item is rated on a 7-point scale, ranging from 1 (not observed) to 7 (very severe), with a total score range from 4-28, where higher scores indicate psychiatric symptoms. MDD participants only.

Time frame:
Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)
Reported as:
Mean · Score on a scale
Change in Brief Psychiatric Rating Scale Positive Domain
Score on a scaleMDD: KetamineMDD: Midazolam
Pre-infusion: Infusion 14.08 ± 0.274.08 ± 0.27
Immediate post-infusion: Infusion 14.11 ± 0.584.04 ± 0.20
1 hr post-infusion: Infusion 14.00 ± 0.004.00 ± 0.00
Pre-infusion: Infusion 24.03 ± 0.194.08 ± 0.28
Immediate post-infusion: Infusion 24.07 ± 0.374.08 ± 0.28
1 hr post-infusion: Infusion 24.00 ± 0.004.08 ± 0.28
Pre-infusion: Infusion 34.00 ± 0.004.04 ± 0.20
Immediate post-infusion: Infusion 34.00 ± 0.004.04 ± 0.20
1 hr post-infusion: Infusion 34.00 ± 0.004.04 ± 0.20
Pre-infusion: Infusion 44.00 ± 0.004.08 ± 0.28
Immediate post-infusion: Infusion 44.07 ± 0.384.08 ± 0.28
1 hr post-infusion: Infusion 44.00 ± 0.004.08 ± 0.28
Study exit (No infusions on study exit, so only 1 timepoint here)4.03 ± 0.184.00 ± 0.00
SecondaryChange in Clinician-Administered Dissociative Symptom Scale

The Clinician-Administered Dissociative States Scale (CADSS) was used before and after each infusion to assess the severity of dissociative symptoms associated with study drug administration. Possible scores range from 0-5 where higher scores indicate worse outcome/more severe symptoms. MDD participants only

Time frame:
Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)
Reported as:
Mean · Score on a scale
Change in Clinician-Administered Dissociative Symptom Scale
Score on a scaleMDD: KetamineMDD: Midazolam
Infusion 1: Pre-infusion0.85 ± 2.070.77 ± 2.03
Infusion 1: Immediate post-infusion12.15 ± 11.180.92 ± 1.79
Infusion 1: 1 hr post-infusion0.44 ± 1.400.11 ± 0.43
Infusion 2: Pre-infusion0.24 ± 0.640.40 ± 0.96
Infusion 2: Immediate post-infusion12.34 ± 16.161.12 ± 2.09
Infusion 2: 1 hr post-infusion0.34 ± 0.900.04 ± 0.20
Infusion 3: Pre-infusion0.14 ± 0.580.24 ± 0.83
Infusion 3: Immediate post-infusion10.48 ± 13.330.46 ± 0.83
Infusion 3: 1 hr post-infusion0.10 ± 0.310.08 ± 0.28
Infusion 4: Pre-infusion0.15 ± 0.440.17 ± 0.56
Infusion 4: Immediate post-infusion9.96 ± 17.610.79 ± 1.74
Infusion 4: 1 hr post-infusion0.04 ± 0.190.08 ± 0.28
Study exit (No infusions on study exit, so only 1 timepoint here)0.29 ± 0.820.19 ± 0.65
SecondaryNumber of Participants Reporting Symptoms From the Patient Rated Inventory of Side Effects (PRISE)

The Patient Rated Inventory of Side Effects (PRISE) is a clinician administered questionnaire used to qualify side effects by identifying and evaluating the tolerability of each symptom. Symptoms are grouped into domains by organ class. Numbers reported here reflect number of participants who reported at least one symptom in a given class over the total study duration, from baseline to study exit. Please note that many "other" side effects are symptoms of depression, and many were present at baseline since this was an MDD population. Here, we report the number of participants who endorsed symptoms from each organ class of symptoms.

Time frame:
Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)
Reported as:
Count of participants · Participants
Number of Participants Reporting Symptoms From the Patient Rated Inventory of Side Effects (PRISE)
ParticipantsMDD: KetamineMDD: Midazolam
Number of participants who reported gastrointestinal symptoms2321
Number of participants who reported heart-related symptoms129
Number of participants who reported skin related symptoms145
Number of participants who reported nervous system related symptoms2721
Number of participants who reported eye/ear related symptoms2511
Number of participants who reported genital/urinary related symptoms53
Number of participants who reported sleep-related symptoms2427
Number of participants who reported sexual functioning-related symptoms1315
Number of participants who reported other symptoms3030
Number of participants reporting distressing gastrointestinal symptoms52
Number of participants reporting distressing heart-related symptoms23
Number of participants reporting distressing skin-related symptoms20
Number of participants reporting distressing nervous system-related symptoms53
Number of participants reporting distressing eye/ear related symptoms31
Number of participants reporting distressing genital/urinary-related symptoms11
Number of participants reporting distressing sleep-related symptoms912
Number of participants reporting distressing sexual functioning-related symptoms46
Number of participants reporting other distressing symptom(s)1615

Adverse events

Collected over From date of informed consent until end of follow-up (maximum of 5 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MDD: Ketamine0/31 (0%)0/31 (0%)11/31 (35.5%)
MDD: Midazolam0/31 (0%)0/31 (0%)5/31 (16.1%)
Healthy Control0/42 (0%)0/42 (0%)1/42 (2.4%)
Most frequent other events
Most frequent other events
EventMDD: KetamineMDD: MidazolamHealthy Control
NauseaGastrointestinal disorders10/311/311/42
HeadacheNervous system disorders4/314/310/42

Baseline characteristics

MDD participants were randomized to receive either ketamine or midalozam infusions

Age, Continuous
Age, Continuous(Years)Healthy ControlsMDD - KetamineMDD - MidazolamTotal
Mean39.9 ± 14.138.0 ± 12.543.0 ± 14.640.3 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)Healthy ControlsMDD - KetamineMDD - MidazolamTotal
Female23251260
Male1961944
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Healthy ControlsMDD - KetamineMDD - MidazolamTotal
American Indian or Alaska Native0000
Asian123419
Native Hawaiian or Other Pacific Islander0101
Black or African American2248
White26212269
More than one race0415
Unknown or Not Reported2002
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Healthy ControlsMDD - KetamineMDD - MidazolamTotal
Hispanic or Latino54110
Not Hispanic or Latino37272993
Unknown or Not Reported0011
08

Study locations

1 site
  • UT Southwestern Medical Center
    Dallas, Texas 75235, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — IPD will be shared based on institutional approval

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Apr 2025, 35 months.

Results were first posted in Oct 2026, 1 year 5 months after primary completion.

Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's 35 months is close to that.

Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2021
First posted
Sep 16, 2021
StartActual
May 5, 2022
Primary completionActual
Apr 30, 2025
CompletionActual
Apr 30, 2025
Results first posted
Oct 8, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 8, 2026
Enrollment
165→104
Oct 8, 2026
Primary outcomes
4 edited
What changed in the outcomes
  • EditedResting state functional connectivityState Functional Connectivity.Time frame: Baseline
  • EditedStriatal responseResponse to frustrative nonrewardFrustrative Nonreward (FNR).Time frame: Baseline
  • EditedTreatment-related changeChange in striatumStriatum-habenula functional connectivityFunctional Connectivity.Time frame: Baseline, at 14 days → Assessed at baseline and end of treatment. See outcome measure 1 for baseline visit reporting
  • EditedTreatment-related changeChange in striatal responseStriatal Response to FNR.Time frame: Baseline, at 14 days → Baseline, at 14 days. See outcome measure 2 for baseline timepoint data
Oct 8, 2026
Secondary outcomes
4 edited, 4 added, 5 removed
What changed in the outcomes
  • EditedChange in symptomsSymptoms of irritability after two weeksIrritability After Two Weeks of twiceTwice-weekly infusionsInfusions of ketamine versus midazolamKetamine Versus Midazolam.Time frame: Baseline, at 14 days → 14 days (end of treatment)
  • EditedChange in symptomsSymptoms of depressionDepression (including suicidal ideationIncluding Suicidal Ideation) measuredMeasured by MADR scaleScaleTime frame: Baseline, at 14 days → 14 days (end of treatment)
  • EditedChange in symptomsSymptoms of depression measuredDepression Measured by QIDS reportReportTime frame: Baseline, at 14 days → 14 days (end of treatment)
  • EditedChange in symptoms including anxious arousal measuredSymptoms of Anxious Arousal Measured by MAS questionnaireQuestionnaireTime frame: Baseline, at 14 days → 14 days (end of treatment)
  • AddedNumber of Participants That Met Criteria for Experiencing an Anger Attack on Massachusetts General Hospital Anger Attack Questionnaire (AAQ)Time frame: Baseline, at 14 days
  • AddedChange in Brief Psychiatric Rating Scale Positive DomainTime frame: Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)
  • AddedChange in Clinician-Administered Dissociative Symptom ScaleTime frame: Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)
  • AddedNumber of Participants Reporting Symptoms From the Patient Rated Inventory of Side Effects (PRISE)Time frame: Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)
  • RemovedChange in behavior (including anger attacks) measured by AAQTime frame: Baseline, at 14 days
  • RemovedChange in severity of dissociative symptoms associated with study drug administration measured by CADS scaleTime frame: Baseline, at 14 days
  • RemovedChange in patient reported side effects measured by PRISE Adverse Event scoresTime frame: Baseline, at 14 days
  • RemovedAcute behavioral changes measured by Brief Psychiatric Rating Scale (BPRS)Time frame: Baseline, at 14 days
  • Removedother outcomeTo evaluate if changes in neurocircuit function with ketamine mediate treatment-related improvement in irritability.Time frame: Up to 14 days
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Results posted
    Enrollment 165→104
    Primary outcomes 4 edited
    What changed in the outcomes
    • EditedResting state functional connectivityState Functional Connectivity.Time frame: Baseline
    • EditedStriatal responseResponse to frustrative nonrewardFrustrative Nonreward (FNR).Time frame: Baseline
    • EditedTreatment-related changeChange in striatumStriatum-habenula functional connectivityFunctional Connectivity.Time frame: Baseline, at 14 days → Assessed at baseline and end of treatment. See outcome measure 1 for baseline visit reporting
    • EditedTreatment-related changeChange in striatal responseStriatal Response to FNR.Time frame: Baseline, at 14 days → Baseline, at 14 days. See outcome measure 2 for baseline timepoint data
    Secondary outcomes 4 edited, 4 added, 5 removed
    What changed in the outcomes
    • EditedChange in symptomsSymptoms of irritability after two weeksIrritability After Two Weeks of twiceTwice-weekly infusionsInfusions of ketamine versus midazolamKetamine Versus Midazolam.Time frame: Baseline, at 14 days → 14 days (end of treatment)
    • EditedChange in symptomsSymptoms of depressionDepression (including suicidal ideationIncluding Suicidal Ideation) measuredMeasured by MADR scaleScaleTime frame: Baseline, at 14 days → 14 days (end of treatment)
    • EditedChange in symptomsSymptoms of depression measuredDepression Measured by QIDS reportReportTime frame: Baseline, at 14 days → 14 days (end of treatment)
    • EditedChange in symptoms including anxious arousal measuredSymptoms of Anxious Arousal Measured by MAS questionnaireQuestionnaireTime frame: Baseline, at 14 days → 14 days (end of treatment)
    • AddedNumber of Participants That Met Criteria for Experiencing an Anger Attack on Massachusetts General Hospital Anger Attack Questionnaire (AAQ)Time frame: Baseline, at 14 days
    • AddedChange in Brief Psychiatric Rating Scale Positive DomainTime frame: Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)
    • AddedChange in Clinician-Administered Dissociative Symptom ScaleTime frame: Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)
    • AddedNumber of Participants Reporting Symptoms From the Patient Rated Inventory of Side Effects (PRISE)Time frame: Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)
    • RemovedChange in behavior (including anger attacks) measured by AAQTime frame: Baseline, at 14 days
    • RemovedChange in severity of dissociative symptoms associated with study drug administration measured by CADS scaleTime frame: Baseline, at 14 days
    • RemovedChange in patient reported side effects measured by PRISE Adverse Event scoresTime frame: Baseline, at 14 days
    • RemovedAcute behavioral changes measured by Brief Psychiatric Rating Scale (BPRS)Time frame: Baseline, at 14 days
    • Removedother outcomeTo evaluate if changes in neurocircuit function with ketamine mediate treatment-related improvement in irritability.Time frame: Up to 14 days
    + 3 other changes: index terms, verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05046184
Responsible party
Manish Jha (Associate Professor, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Sep 16, 2021
Start date
May 5, 2022
Primary completion
Apr 30, 2025
Completion
Apr 30, 2025
Results posted
Oct 8, 2026
Last update
Oct 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion